Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/1/18 (What's New)

Summary

  • Determination must be made as to likelihood that at least 2—if not 3—fully active drugs can be combined in next regimen
    • Unless a boosted PI is likely to be fully active, the use of < 2 fully active drugs is associated with high risk of selecting for resistance to any new drugs and further limiting future treatment options
  • Evidence-based management standards argue for inclusion of NRTIs and ritonavir-boosted PIs in new regimens for treatment-experienced patients
    • Managing Integrase Inhibitor–Experienced Patients
        Repeat Tropism Testing and the Role of CCR5 Antagonists in Treatment-Experienced Patients
          ARV Agents Approved Specifically for Heavily Treatment–Experienced Patients With Multidrug Resistance

          Action required